Topsalysin - Sophiris Bio

Drug Profile

Topsalysin - Sophiris Bio

Alternative Names: PRX-302; PSA-PA 1; PSA-PAH 1

Latest Information Update: 22 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University; University of Victoria
  • Developer Sophiris Bio
  • Class Antineoplastics; Bacterial toxins; Pore forming cytotoxic proteins; Urologics
  • Mechanism of Action Apoptosis stimulants; Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Benign prostatic hyperplasia
  • Phase II Prostate cancer

Most Recent Events

  • 25 Jun 2018 Interim safety and efficacy data from a phase IIb trial in Prostate cancer released by Sophiris Bio
  • 24 Jun 2018 Biomarkers information updated
  • 21 Mar 2018 Independent data monitoring committee (IDMC) recommends to continue phase IIb trial for Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top